RxDoctor Payments Data

Giovanni Rodriguez

Family · Chicago, ILNPI 1174021893

Payments from drug & device makers

$3,491in general payments, 2019–2025

Across 119 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$567
  • AbbVie$324
  • Baxter Healthcare$225
  • Novo Nordisk$203
  • Lilly USA, LLC$200
  • plus $908 from 12 others

What the payments were for

  • Consulting fees$2256%
  • Food & beverage$3,26694%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,491 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$98,608
RybelsusSemaglutide37$94,584
OzempicSemaglutide53$75,450
FarxigaDapagliflozin Propanediol66$75,081
TradjentaLinagliptin42$53,274
EliquisApixaban28$36,644
CreonLipase/Protease/Amylase12$36,193
MounjaroTirzepatide27$28,185
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$27,343
EntrestoSacubitril/Valsartan20$23,310
GemtesaVibegron18$10,845
RestasisCyclosporine12$8,574
Sucralfate20$8,353
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,765
Humalog Kwikpen U-100Insulin Lispro17$3,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$203$170,03490 claims
Boehringer IngelheimJardiance, Tradjenta$567$151,882109 claims
AstraZenecaFarxiga$1,064$75,08166 claims
AbbVieCreon, Restasis$324$44,76724 claims
PfizerEliquis$100$36,64428 claims
GSKTrelegy Ellipta, Shingrix$14$30,50541 claims
Lilly USA, LLCMounjaro$200$28,18527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.

Other family in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →